Vladimir P. Torchilin is a University Distinguished Professor and Director, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston. He graduated from the Moscow University with MS in Chemistry, and obtained there his Ph.D. and D.Sc. in Polymer Chemistry and Chemistry of Physiologically Active Compounds in 1971 and 1980, respectively. In 1991, Dr. Torchilin joined MGH/Harvard Medical School as the Head of Chemistry Program, Center for Imaging and Pharmaceutical Research, and Associate Professor of Radiology. Since 1998 Dr. Torchilin is with Northeastern University. He was the Chair of the Department of Pharmaceutical Sciences in 1998-2008. His research interests include drug delivery and targeting, pharmaceutical nanocarriers. He has published more than 350 original papers, more than 150 reviews and book chapters, wrote and edited 10 books, including Immobilized Enzymes in Medicine, Targeted Delivery of Imaging Agents, Liposomes, Nanoparticulates as Pharmaceutical Carriers, and holds more than 40 patents. He is Editor-in-Chief of Current Drug Discovery Technologies and of Drug Delivery and on the Editorial Boards of many journals including Journal of Controlled Release (Review Editor), Bioconjugate Chemistry, Advanced Drug Delivery Reviews. Among many awards, Professor Torchilin was the recipient of the 1982 Lenin Prize in Science (the highest award in the USSR). He is a Member of European Academy of Sciences. He is also a Fellow of AIMBE, AAPS, and CRS, and received the 2005 Research Achievements in Pharmaceutics and Drug Delivery Award from the AAPS, 2007 Research Achievements Award from the Pharmaceutical Sciences World Congress, 2009 AAPS Journal Award, 2009 International Journal of Nanomedicine Distinguished Scientist Award, 2010 CRS Founders Award, and 2012 Alec Bangham Award. In 2005-2006 he was a President of the Controlled Release Society. In 2011, Times Higher Education ranked him number 2 among top world scientists in pharmacology for the period of 2001-2010. herapy and Micellar tumor targeting.
Vladimir Torchilin(Research Area)
Physiologically active polymers and their use as drug carriers, Targeted delivery of therapeutic and diagnostic agents, Experimental diagnostic imaging, Experimental tumor immunology and therapy and Micellar tumor targeting.
Taosheng Chen completed his Ph.D. from the University of Vermont, and postdoctoral studies from the University of Virginia. He is an Associate Member (Associate Professor) and Director of the High Throughput Screening Center at St. Jude Childrenâ€™s Research Hospital. Prior to joining St Jude, Taosheng was a Senior Research Investigator at Bristol-Myers Squibb, and a Research Scientist at SAIC-Frederick, National Cancer Institute. Taosheng serves on the Editorial Boards of several journals, and on NIH Grant Review Panels. He has authored more than 80 publications. His research laboratory studies the roles of nuclear receptors in therapeutic efficacy and toxic effects (http://www.stjuderesearch.org/chen/).
Taosheng Chen(Research Area)
Research interest include Regulation of PXR and CAR in drug toxicity, drug resistance and human diseases ,development of drug discovery technologies and high throughput screening (HTS) and high content screening (HCS)
Esmaiel Jabbari is Tenured Full Professor of Chemical and Biomedical Engineering at the University of South Carolina. He directs the biomaterials, tissue engineering, and drug delivery laboratory which specialize on the design of 3D multi-cellular co-culture systems to study the effect of nanoscale spatiotemporal delivery of morphogens and physico-mechanical factors on the fate of stem cells. He has received numerous awards for his research program including the Berton Rahn Award in 2012 from the AO Foundation, the Stephen Milam Award in 2008 from the Oral and Maxillofacial Surgery Foundation, and elected for the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE) in 2013. He is the author of more than 250 books, book chapters, refereed journal articles and conference proceedings and he has mentored more than 130 scholars. He has served as the Academic Editor for PLOS ONE.
Esmaiel Jabbari(Research Area)
Bioinspired materials, Skeletal tissue engineering, Multiâ€scale composite materials, Self-assembled nanogels for growth factor delivery, Drug targeting to cancer stem cells, Stem cell encapsulation and delivery, Three-dimensional tissue models
r. Alain L Fymat is a medical scientist and an educator. He was educated at the University of Paris-Sorbonne and the University of California at Los Angeles. He is the current President/CEO and Professor at the International Institute of Medicine and Science with a previous appointment as Executive Vice President, Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine. He was formerly Professor of Radiology, Radiological Sciences, Radiation Medicine (Oncology), Critical Care Medicine, and Physics at several U.S. and European Universities. Previously, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs, Veterans Health Administration (Office of Research Oversight), and Director of the Magnetic Resonance Imaging Center and for a time Acting Chair of Radiology at its Loma Linda, California Medical Center. He has extensively published (~ 350 publications including patents, books & monographs, book chapters, refereed articles) and has lectured extensively in the USA, Africa and Asia. He has been the recipient of numerous research grants from government, academia and private industry, and has consulted extensively with these entities. He is Honorable Editor of the International Journal of Cancer Prevention and Current Research and the International Journal of Nanomedicine Research. He s also Editor of the Global Journal of Nanomedicine and the Journal of Nanobiotechnology. He is a Board member of several institutions and Health Advisor of the American Heart & Stroke Association (Coachella Valley Division, California).
Alain L Fymat(Research Area)
Dr. Fymatâ€™s current research interests lie at the interface between science and medicine, particularly molecular/personal/precision medicine, nanomedicine, human genetics/epigenetics/ecogenetics, and pharmacogenomics. His most recent publications deal with magnetic resonance Imaging with nanocontrasting materials, nanotechnology and cancer, nanochemotherapy, nanoneurology, natural and synthetic immunotherapy, drug delivery including across the brain protective barriers, and drug manufacturing in Africa.
Dr Higgins currently is a Senior Director and Global Technology Lead in the Discovery Pharmaceutical Sciences department at Merck Research Labs as well as an Adjunct Professor at the University of Pennsylvania School of Medicine, Dept. of Systems Pharmacology and Translational Therapeutics.
John D. Higgins(Research Area)
Recent emphasis on oral peptide delivery and long acting implants. Develop strategies and execute on new technologies in drug delivery,
pharmaceutics and innovative administration routes/dosage forms.
Uday Kompella is a Professor of Pharmaceutical Sciences, Ophthalmology, and Bioengineering at the University of Colorado Denver. A key focus of Dr. Kompellaâ€™s research is the application of nanotechnology for drug delivery, gene delivery, and imaging. Dr. Kompella has published research in more than 150 scientific papers and book chapters, and he has coedited three books: Nanoparticle Technology for Drug Delivery, Supercritical Fluid Technology for Drug Product Development, and Drug Product Development for the Back of the Eye. Dr. Kompella received his B.Pharm (Hons) from the Birla Institute of Technology and Science, Pilani, his M.Pharm (Pharmaceutical Engineering) from Jadavpur University, Kolkata, and his Ph.D. in Pharmaceutical Sciences from the University of Southern California, Los Angeles. Before joining the University of Colorado, Dr. Kompella served as a faculty member at the University of Nebraska Medical Center and Auburn University. Dr. Kompella has served as a Chairman of the Regulatory Sciences Section of the American Association of Pharmaceutical Scientists (AAPS), the Books Editorial Advisory Group of the AAPS, the Ocular Drug Delivery and Disposition Focus Group of the AAPS, and the Pharmaceutical Sciences Graduate Program at the University of Nebraska Medical Center. Dr. Kompella is a recipient of the New Investigator Grant in Pharmaceutics and Pharmaceutical Technologies from the AAPS, an Undergraduate Teaching Excellence Award from the Alumni Association of Auburn University, Distinguished Scientist and Distinguished Teacher awards from the University of Nebraska Medical Center, a Deanâ€™s Mentoring Award from the University of Colorado Anschutz Medical Campus, and an ARVO Foundation/Pfizer/Carl Camras Translational Research Award in Ophthalmology from ARVO. Dr. Kompella is a Fellow of the AAPS and ARVO. In addition to serving as an editor for Pharmaceutical Research, Dr. Kompella served as an editor for Clinical Research and Regulatory Affairs and currently serves as the Editor-in-Chief for the journal Expert Opinion on Drug Delivery and as an Associate Editor for the Journal of Ocular Pharmacology and Therapeutics.
Uday B. Kompella(Research Area)
Research area include Nanotechnology for drug delivery, gene delivery, and imaging; Ocular, nasal, and pulmonary delivery; Supercritical fluid technology for delivery systems.
Professor Dr. Luisa MarÃa Arvide Cambra, Spanish is now Professor with Chair at the University of AlmerÃa (Spain) and she was Lecturer at the University of Granada.
Thirty six years of the teaching and researching experience. She is Director of Research Group HUM113-Estudios FilolÃ³gicos from Program of Research of Andalusian Government, where she has managed and directed several academic and scientific contracts and research projects, as well as Member of European Scientific Institute (ESI) management team, and Athens Institute for Education & Research (ATINER), etc.
She is author of a many works on several aspects of the Arabic science and literature in the Middle Ages, as well as Arabic language and linguistics. She has also participated in different prestigious international scientific Conferences. She has visited a many universities and academic institutions of Europe, United States and Arab countries in order to teach and research. Among her works, we have the study and the translation to Spanish of some treatises of Kitab al-tasrifÂ´s Al-Zahrawi, Ibn QutaybaÂ´s texts, Maqamas of Al-Hariri, The Sicilian Questions of Ibn SabÂ´in, etcetera. 11 books and over 90 articles and papers published in prestigious international journals and proceedings.Included and enlisted in 2000 Outstanding Intellectuals of the 21st Century 2011. International Biographical Centre. Cambridge, UK.Included and enlisted in Great Minds of 21st Century, American Biographical Institute. Raleigh, North Carolina, USA.Honored as Woman of the Year 2011 by the American Biographical Institute. Raleigh, North Carolina, USA.Reviewer and Member of the Editorial Board in several renowned international journals as well as member of the organizing, scientific & academic committee at prestigious international conferences
Luisa Maria Arvide Cambra(Research Area)
Medieval Arabic Science History of Medicine Philological Studies Humanities
Kamalinder K Singh is Professor of Pharmaceutical Technology and Drug delivery at School of Pharmacy and Biomedical Sciences, University of Central Lancashire. After graduating from Panjab University, Chandigarh, Kamalinder joined SNDT Womenâ€™s University, Mumbai in 1984 as Lecturer in Pharmaceutics and subsequently promoted to Reader in 1993 and Professor of Pharmaceutics in 2001 and later held the position of Principal C. U Shah College of Pharmacy within SNDT Womenâ€™s University.
She has supervised over 20 Ph. D students and ongoing research programmes focus on nanoparticulate drug delivery systems including protein based nanoparticles, lipid nanostructures, nanosuspensions, lipospheres, microspheres, taste masking and nanophytopharmaceuticals and span the following areas of development; pre-formulation; formulation development; physicochemical assessment; stability assessment and prediction; in-vitro performance tests, transport; pharmacokinetics and bio-distribution and in vitro-in vivo correlation. These drug delivery strategies are primarily being investigated for cancer, parasitic diseases and dermatological conditions either alone or in combination to prepare mixed nano-systems for delivery of single drug or co-delivery of multi-agents. She has particular research interest in development of nanocarrier systems for selective targeting to parasitized RBCs for effective treatment of malaria. She has a number of successful collaborations with other universities, and pharmaceutical industry leading to publications and development of new products and hold several patents in the pharmaceutical area.
KAMALINDER K SINGH(Research Area)
Nanomedicine and Innovative technologies and Drug design, analysis and delivery research group
Mingzhong is a Principal Lecturer in Pharmaceutical Technologies group in the School of Pharmacy at De Montfort University. He was awarded a PhD in Control and Instrumentation Engineering in 1998 from Northeastern University in China. He had been working as a post doctoral researcher at a number of universities: University of Oxford, Heriot-Watt University and the Hong Kong University of Science and Technology.
Mingzhong Li(Research Area)
His research interests are particle characterisation, multiphase fluid-flow modelling, and on-line process monitoring and control for pharmaceutical processes, such as crystallisation, fluidised bed dryer and freeze-drying processes. He is also interested in developing analytical methods to retrieve particle size distribution from measurements by different instruments: UV-vis spectroscopy, ultrasound, image analysis and Focused-bean reflection measurement (FBRM)
Dr Abbas Amini is an assistant professor at the Australian College of ACK and Western Sydney University, and the member of graduate supervisory board. After obtaining PhD, he conducted research with other Australian universities, as a postdoctoral research fellow at Monash and Deakin Universities, and as a senior research fellow at the University of Melbourne. His fine outcomes have been presented in high impact factor journals, e.g., Nature publication group, and a recent published book in 2016. Abbas is the editor of more than 10 reputed journals, and the committee member of more than 100 international conferences.
Andrea Nicolini is past aggregate Professor at the Department of Oncology, Pisa University. His research over the past 20 years was mainly devoted to the field of breast and colorectal cancer, particularly the use of serum tumor markers in the "early" detection and treatment of metastatic disease and the function of cell mediated immunity. The role of immunotherapy combined with conventional antiestrogen therapy to overcome the arising of resistance in endocrine dependent metastatic breast cancer was another main explored research field. Dr. Nicolini has published about 250 original papers/review articles (including book chapters), most of them in peer reviewed Journals with I.F. He takes part of the Editorial Board of a few high rank scientific Journals and regularly serves as reviewer for them and many others.
Andrea Nicolini(Research Area)
Research include Immunology and immunotherapy of cancer, thyroid tumours, malignant solid tumours in particular breast cancer, tumour markers.
Professor Konstantinos Avgoustakis has obtained his PhD in Pharmaceutics from the Kingâ€™s College, University of London, UK. He is working as Professor of Pharmaceutical Technology in the Department of Pharmacy, University of Patras, Greece
Konstantinos Avgoustakis(Research Area)
He is also an affiliated investigator in Biomedical Research Foundation of Academy of Athens (BRFAA). His research interests lie in the field of controlled drug delivery using engineered nanoparticles and the development of formulations for the efficient delivery of drugs with limited aqueous solubility. He has published 63 papers in peer reviewed journals and is the inventor of one European patent. His work has received more than 3000 citations.
Dr Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980. Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences, National Center for Immunology (Russia), NIH, Bethesda, USA, and British Society forImmunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Professor of I.M. Sechenov First Moscow State Medical University and of A.I.Evdokimov Moscow State Medical & Dental University. From 2007, Suchkov is the First Vice-President and Dean of School of PPPM Politics and Management of the University of World Politics and Law. In 1991-1995, Dr Suchkov was a Scientific Secretary-in-Chief of the Editorial Board of the Interna-tional Journalâ€œBiomedical Scienceâ€ (Russian Academy of Sciences and Royal Society of Chemistry, UK) and TheInternational Publishing Bureau at the Presidium of the Russian Academy of Sciences. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Dis-eases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Person-alized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology, EPMA J., and Personalized Medicine Universe, and others. Dr Suchkov is known as a co-author of the Concept of post-infectious clinical and immunological syn-drome, co-author of a concept of abzymes and their impact into the pathogenesis ofautuimmunity conditions, and as one of the pioneers in promoting the Concept of PPPM into a practical branchof health services. Now r Suchkov is a Chair of Dept for Personalized & Translational Medicine, and Director, Center for Personalized & Translational Reproductology, I.M.Sechenov First Moscow State Medical University. Prof Sergey Suchkov, MD, PhD Chair, Dept for Personalized and Translational Medicine, Director, Center for Personalized Reproductology & Pediatrics, I.M.Sechenov First Moscow State Medical University, Moscow, Russia Member, EPMA, Brussels, EU Member, PMC, Washington, DC, USA Member, ISPM, Tokyo, Japan Member, New York Academy of Sciences Member, ACS, USA Member, AHA, USA Member, AMEE, Dundee, UK Secretary General, UCC, Cambridge, UK
Sergey Suchkov(Research Area)
Predictive, Preventive and Personalized Medicine,Immunology, Medicine, Pathology
Oleg Gradov is a Faculty of Institute for Energy Problems of Chemical Physics, RAS, Moscow, bld. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect in his wide range of publications in various national and international journals. He is published one of article is In Situ Tunable Laser Diode Spectroscopy OF The Processes and Products OF The Microwave-Induced Self-Organization In The Soft Mater Active Media. His Research interests are Photoinduced Self-Organization, Self-Oscillations, Self-Focusing, CAD, CAE, d'Arcy-Thompson, Artificial Cells, Morphogenesis, Abiogenesis.
Prof. Sinerik Ayrapetyan has completed his PhD in Cell Biophysics in the Institute of Physiology of Ukraine Academy of Sciences, Kiev. He is the head of Research Council and the coordinator of UNESCO Chair in Life Sciences at Life Sciences International Postgraduate Educational Center, Yerevan, Armenia. His current research interest is â€œIntracellular Signaling System in Norm and Pathologyâ€. He has published 7 international books and 115 papers. He is serving as a Chief Editor for the Journal of â€œBioequivalence and Bioavailabilityâ€, â€œBiomedical Engineering Current Researchâ€ and â€œBasic, Applied Pharmacy and Pharmacologyâ€ and a member of editorial board of the journals: "Electromagnetic Biology and Medicine", "Journal of International Dental and Medical Research", â€œISRN Biophysicsâ€, â€œAdvances in Life Sciences", â€œApplied Pharmacyâ€, â€œEuropean Journal of Biophysicsâ€, â€œBiochimica et Biophysica Actaâ€ etc. He is a member of International Coordination Council of WHO and number of professional international societies.
Sinerik Ayrapetyan(Research Area)
Current research interest is â€œIntracellular Signaling System in Norm and Pathologyâ€
Anne Grobler is a South African citizen with a Ph.D. in Pharmaceutics (North-West University, South Africa), an M.Sc. in Medical Biochemistry (Stellenbosch University, South Africa) and an Honours in Biochemistry (PU for CHE, South Africa). In 2010 she was appointed as associate professor in the Dept. of Pharmaceutics and as coordinator of commercialization for the Faculty of Health Sciences. She has delivered a number of M.Sc. and Ph.D. students and is currently promoter of 7 Ph.D. and study leader of 3 M.Sc. students. Anne was instrumental in the successful bidding and establishment of the national South African Preclinical Drug Development Platform for the Department of Science and Technology at the NWU. In 2013 she was appointed as the director of this platform. She has authored/co-authored 31 peer-reviewed international publications and book chapters and numerous international and national conference proceedings. Her passion for innovation is reflected in the NWU patent portfolio; she is the main inventor/author of 7 patents granted in multiple countries.
Anne Grobler(Research Area)
Her research interests are the design, construction and optimization of delivery and transporter technologies for active pharmaceutical in conjunction with the preclinical and clinical evaluation of such technologies. This interest includes the delivery and transport of bio-agricultural molecules and compounds.
He has completed his Masters and doctorate in pharmacy from Andhra University, Hyderabad. He is having vast experience in academics as well as administration. Currently he is working as Professor, Pharmaceutics at Delhi Institute of Pharmaceutical Sciences and Research.
Pravat Kumar Sahoo(Research Area)
He has vast experience in Pharmaceutics and nanotechnology
Mohamed Eddouks is Professor at Moulay Ismail University, Faculty of Sciences and Techniques Errachidia, Morocco. He is a researcher in Physiology and Pharmacology with a Master Degree in Metabolic and Molecular Endocrinology from University of Paris vi, a specialized certificate in Endocrine Pharmacology from University of Paris vii and PhD degrees in Physiology and Pharmacology from University of Liege, Belgium and Sidi Mohammed Ben Abdellah University, Fez, Morocco. After his post-doctoral fellowship at Department of Physiology, Faculty of Medicine of Montreal, Canada, he is working for the last 16 years on medicinal plants. His work on antidiabetic and antihypertensive plants is well recognized globally. His research focuses on ethnobiological as well as pharmacological issues in the use of Moroccan medicinal plants for the treatment of diabetes mellitus, obesity and hypertension. His contribution to this field includes four international books and more than 80 peer-reviewed articles and book chapters of international repute. He is Guest Editor of American Journal of Pharmacology and Toxicology, Lead Guest Editor of an annual special issue published by Evidence-Based and Complementary Alternative Medicine, Regional Editor of the Following journals: American Journal of Food Technology, Journal of Applied Sciences, Trends in Applied Sciences Research and Singapore Journal of Scientific research, Member of Editorial Board of several international journals. He has been honored with the first Prize of Scientific Research in 2008 by the Moroccan Association of Research and Development and the first Prize of the Federation of Arab Scientific Councils in 2016. He has been the Dean of Polydisciplinary Faculty of Errachidia from 2008 to 2012.
Mohamed Eddouks (Research Area)
He worked on medicinal plants, antidiabetic and antihypertensive plants. His research focuses on ethnobiological as well as pharmacological issues in the use of Moroccan medicinal plants for the treatment of diabetes mellitus, obesity and hypertension